Table 4 Perioperative outcome for patients underwent salvage liver resection

From: Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study

Variables

LENTAP (n = 42)

TACE (n = 13)

P value

Hospital stays after surgery (days)

9.17 ± 5.11

8.54 ± 3.66

0.683

Preoperative AFP, n (%)

  

0.756

 Normal

25 (59.5)

7 (53.8)

 

 Elevated

17 (40.5)

6 (46.2)

 

Extent of resection, n (%)

  

0.480

 Major

33 (78.6)

9 (69.2)

 

 Minor

9 (21.4)

4 (30.8)

 

Operation duration (min)

224.00 ± 96.09

211.54 ± 82.749

0.675

HIO (Min)

43.00 ± 24.25

26.77 ± 24.54

0.027

Intraoperative blood loss (mL)

514.29 ± 455.63

424.62 ± 429.197

0.533

Transfusion, n (%)

  

1.00

 Yes

10 (23.8)

3 (23.1)

 

 No

32 (76.2)

10 (76.9)

 

Pathological response, n (%)

   

 pCR

17 (40.5)

0 (0)

0.005

 MPR

30 (71.4)

3 (23.1)

0.003

Microvascular invasion, n (%)

  

0.427

 Present

7 (16.7)

4 (30.8)

 

 Absent

35 (83.3)

9 (69.2)

 

Clavien-Dindo classification, n (%)

  

0.664

 0~Ⅱ

35 (83.3)

12 (92.3)

 

 Ⅲ~Ⅳ

7 (16.7)

1 (7.7)

 
  1. AFP alpha-fetoprotein, HIO hepatic inflow occlusion, pCR pathologic complete response, MPR major pathologic response